Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Lymphoma Myeloma. 2009 Mar;9(1):59-61. doi: 10.3816/CLM.2009.n.015.

Rituximab-based treatments in Waldenström's macroglobulinemia.

Author information

  • 1Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece. mdimop@med.uoa.gr

Abstract

The anti-CD20 monoclonal antibody rituximab has shown activity in approximately one third of patients with Waldenström's Macroglobulinemia (WM). Because this agents is nonmyelosuppressive, several studies have assessed its combination with chemotherapeutic agents such as fludarabine, cladribine, cyclophosphamide, and doxorubicin. These regimens induce at least partial response in > 70% of previously untreated patients. Recent data suggest that prolonged exposure to nucleoside-containing regimens should be avoided because of concerns of myelodysplasia and disease transformation. Rituximab has also been combined with thalidomide, which is an active and nonmyelosuppressive regimen. The rituximab-based combination represents today the most commonly used primary treatment for WM.

PMID:
19362975
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk